Actinium Pharmaceuticals (ATNM) Competitors

$1.17 -0.08 (-6.40%)

Closing price 04:00 PM Eastern

Extended Trading

$1.17 0.00 (0.00%)

As of 06:51 PM Eastern

ATNM vs. IMDX, MENS, PLYX, PLX, and HURA

Should you buy Actinium Pharmaceuticals stock or one of its competitors? MarketBeat compares Actinium Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Actinium Pharmaceuticals include Oncocyte (IMDX), Jyong Biotech (MENS), Polaryx Therapeutics (PLYX), Protalix BioTherapeutics (PLX), and TuHURA Biosciences (HURA). These companies are all part of the "pharmaceutical products" industry.

How does Actinium Pharmaceuticals compare to Oncocyte?

Actinium Pharmaceuticals (NYSE:ATNM) and Oncocyte (NASDAQ:IMDX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

Actinium Pharmaceuticals presently has a consensus target price of $4.50, indicating a potential upside of 284.62%. Oncocyte has a consensus target price of $12.00, indicating a potential upside of 88.98%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Actinium Pharmaceuticals is more favorable than Oncocyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Actinium Pharmaceuticals has a beta of -0.11, indicating that its stock price is 111% less volatile than the broader market. Comparatively, Oncocyte has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market.

In the previous week, Actinium Pharmaceuticals had 2 more articles in the media than Oncocyte. MarketBeat recorded 6 mentions for Actinium Pharmaceuticals and 4 mentions for Oncocyte. Actinium Pharmaceuticals' average media sentiment score of 0.83 beat Oncocyte's score of 0.59 indicating that Actinium Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actinium Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncocyte	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

27.5% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 55.3% of Oncocyte shares are held by institutional investors. 0.6% of Actinium Pharmaceuticals shares are held by company insiders. Comparatively, 2.1% of Oncocyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Actinium Pharmaceuticals has higher earnings, but lower revenue than Oncocyte. Oncocyte is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$90K	407.88	-$48.82M	-$0.75	N/A
Oncocyte	$1.95M	105.20	-$50.22M	-$1.48	N/A

Actinium Pharmaceuticals has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Oncocyte's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Oncocyte	-2,454.64%	N/A	-96.96%

Summary

Actinium Pharmaceuticals beats Oncocyte on 11 of the 16 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to Jyong Biotech?

Jyong Biotech (NASDAQ:MENS) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Actinium Pharmaceuticals has a consensus price target of $4.50, suggesting a potential upside of 284.62%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Actinium Pharmaceuticals had 3 more articles in the media than Jyong Biotech. MarketBeat recorded 6 mentions for Actinium Pharmaceuticals and 3 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 1.31 beat Actinium Pharmaceuticals' score of 0.83 indicating that Jyong Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jyong Biotech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Actinium Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Jyong Biotech has higher earnings, but lower revenue than Actinium Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jyong Biotech	N/A	N/A	N/A	N/A	N/A
Actinium Pharmaceuticals	$90K	407.88	-$48.82M	-$0.75	N/A

27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 0.6% of Actinium Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Jyong Biotech's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jyong Biotech	N/A	N/A	N/A
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Summary

Actinium Pharmaceuticals beats Jyong Biotech on 7 of the 10 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to Polaryx Therapeutics?

Actinium Pharmaceuticals (NYSE:ATNM) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Actinium Pharmaceuticals presently has a consensus price target of $4.50, indicating a potential upside of 284.62%. Polaryx Therapeutics has a consensus price target of $10.00, indicating a potential upside of 262.32%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Actinium Pharmaceuticals is more favorable than Polaryx Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Actinium Pharmaceuticals had 2 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 6 mentions for Actinium Pharmaceuticals and 4 mentions for Polaryx Therapeutics. Polaryx Therapeutics' average media sentiment score of 1.05 beat Actinium Pharmaceuticals' score of 0.83 indicating that Polaryx Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actinium Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Polaryx Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Polaryx Therapeutics has lower revenue, but higher earnings than Actinium Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$90K	407.88	-$48.82M	-$0.75	N/A
Polaryx Therapeutics	N/A	N/A	N/A	N/A	N/A

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 0.6% of Actinium Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Polaryx Therapeutics' return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Polaryx Therapeutics	N/A	N/A	N/A

Summary

Actinium Pharmaceuticals beats Polaryx Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to Protalix BioTherapeutics?

Actinium Pharmaceuticals (NYSE:ATNM) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Actinium Pharmaceuticals has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

Actinium Pharmaceuticals has a beta of -0.11, suggesting that its stock price is 111% less volatile than the broader market. Comparatively, Protalix BioTherapeutics has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market.

Protalix BioTherapeutics has higher revenue and earnings than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$90K	407.88	-$48.82M	-$0.75	N/A
Protalix BioTherapeutics	$76.38M	2.01	$8.31M	$0.18	10.61

Actinium Pharmaceuticals currently has a consensus price target of $4.50, suggesting a potential upside of 284.62%. Protalix BioTherapeutics has a consensus price target of $12.00, suggesting a potential upside of 528.27%. Given Protalix BioTherapeutics' higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

27.5% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 0.6% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 6.5% of Protalix BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Protalix BioTherapeutics had 4 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 10 mentions for Protalix BioTherapeutics and 6 mentions for Actinium Pharmaceuticals. Actinium Pharmaceuticals' average media sentiment score of 0.83 beat Protalix BioTherapeutics' score of 0.24 indicating that Actinium Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actinium Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protalix BioTherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Protalix BioTherapeutics beats Actinium Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to TuHURA Biosciences?

TuHURA Biosciences (NASDAQ:HURA) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

Actinium Pharmaceuticals' return on equity of -100.85% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-164.71%	-105.82%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

TuHURA Biosciences has a beta of -0.01, indicating that its stock price is 101% less volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of -0.11, indicating that its stock price is 111% less volatile than the broader market.

TuHURA Biosciences presently has a consensus target price of $9.00, indicating a potential upside of 252.94%. Actinium Pharmaceuticals has a consensus target price of $4.50, indicating a potential upside of 284.62%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than TuHURA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 0.2% of TuHURA Biosciences shares are owned by company insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

TuHURA Biosciences has higher earnings, but lower revenue than Actinium Pharmaceuticals. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A
Actinium Pharmaceuticals	$90K	407.88	-$48.82M	-$0.75	N/A

In the previous week, Actinium Pharmaceuticals had 1 more articles in the media than TuHURA Biosciences. MarketBeat recorded 6 mentions for Actinium Pharmaceuticals and 5 mentions for TuHURA Biosciences. Actinium Pharmaceuticals' average media sentiment score of 0.83 beat TuHURA Biosciences' score of -0.19 indicating that Actinium Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TuHURA Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Actinium Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Actinium Pharmaceuticals beats TuHURA Biosciences on 10 of the 14 factors compared between the two stocks.

Get Actinium Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATNM vs. The Competition

Export

Metric	Actinium Pharmaceuticals	Pharmaceutical Industry	Medical Sector	NYSE Exchange
Market Cap	$36.71M	$907.68M	$6.23B	$22.81B
Dividend Yield	N/A	4.84%	2.80%	4.12%
P/E Ratio	-0.84	1.49	20.66	29.86
Price / Sales	407.88	115.22	546.74	92.41
Price / Cash	N/A	20.07	27.48	18.80
Price / Book	0.89	8.47	9.67	4.59
Net Income	-$48.82M	-$3.49M	$3.56B	$1.07B
7 Day Performance	-12.69%	6.82%	-1.91%	-1.35%
1 Month Performance	-10.00%	78.52%	-2.65%	-1.29%
1 Year Performance	-29.94%	141.71%	31.17%	21.88%

Actinium Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATNM Actinium Pharmaceuticals	3.2245 of 5 stars	$1.17 -6.4%	$4.50 +284.6%	-25.1%	$36.71M	$90K	N/A	30	Gap Up
IMDX Oncocyte	3.0495 of 5 stars	$4.98 +1.4%	$12.00 +141.0%	N/A	$158.53M	$4.05M	N/A	120	Earnings Report Analyst Upgrade
MENS Jyong Biotech	N/A	$2.09 +1.0%	N/A	N/A	$157.38M	N/A	N/A	31	Positive News Earnings Report
PLYX Polaryx Therapeutics	3.8028 of 5 stars	$3.28 -3.2%	$10.00 +204.9%	N/A	$154.26M	N/A	N/A	11	Positive News Earnings Report Gap Up
PLX Protalix BioTherapeutics	2.9139 of 5 stars	$1.91 -1.5%	$12.00 +528.3%	+18.6%	$153.89M	$52.74M	N/A	200	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ATNM) was last updated on 5/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Actinium Pharmaceuticals (ATNM) Competitors

ATNM vs. IMDX, MENS, PLYX, PLX, and HURA

How does Actinium Pharmaceuticals compare to Oncocyte?

Summary

How does Actinium Pharmaceuticals compare to Jyong Biotech?

Summary

How does Actinium Pharmaceuticals compare to Polaryx Therapeutics?

Summary

How does Actinium Pharmaceuticals compare to Protalix BioTherapeutics?

Summary

How does Actinium Pharmaceuticals compare to TuHURA Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM vs. The Competition

Actinium Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Actinium Pharmaceuticals (ATNM) Competitors

ATNM vs. IMDX, MENS, PLYX, PLX, and HURA

How does Actinium Pharmaceuticals compare to Oncocyte?

Do analysts prefer ATNM or IMDX?

Which has more volatility and risk, ATNM or IMDX?

Does the media prefer ATNM or IMDX?

Do institutionals and insiders believe in ATNM or IMDX?

Which has better earnings and valuation, ATNM or IMDX?

Is ATNM or IMDX more profitable?

Summary

How does Actinium Pharmaceuticals compare to Jyong Biotech?

Do analysts rate MENS or ATNM?

Does the media refer more to MENS or ATNM?

Which has preferable earnings & valuation, MENS or ATNM?

Do institutionals & insiders hold more shares of MENS or ATNM?

Is MENS or ATNM more profitable?

Summary

How does Actinium Pharmaceuticals compare to Polaryx Therapeutics?

Do analysts rate ATNM or PLYX?

Does the media favor ATNM or PLYX?

Which has higher valuation and earnings, ATNM or PLYX?

Do insiders & institutionals have more ownership in ATNM or PLYX?

Is ATNM or PLYX more profitable?

Summary

How does Actinium Pharmaceuticals compare to Protalix BioTherapeutics?

Is ATNM or PLX more profitable?

Which has more risk and volatility, ATNM or PLX?

Which has preferable valuation and earnings, ATNM or PLX?

Do analysts recommend ATNM or PLX?

Do insiders and institutionals hold more shares of ATNM or PLX?

Does the media prefer ATNM or PLX?

Summary

How does Actinium Pharmaceuticals compare to TuHURA Biosciences?

Is HURA or ATNM more profitable?

Which has more volatility & risk, HURA or ATNM?

Do analysts prefer HURA or ATNM?

Do institutionals & insiders believe in HURA or ATNM?

Which has better earnings and valuation, HURA or ATNM?

Does the media favor HURA or ATNM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM vs. The Competition

Actinium Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools